Search Results for "androgens"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for androgens. Results 61 to 70 of 74 total matches.
Comparison Chart: Some Drugs for HFrEF
The Medical Letter on Drugs and Therapeutics • May 26, 2025 (Issue 1729)
inhibitor, or ARB and in those with renal impairment.
.
Spironolactone has anti-androgenic activity ...
View the Comparison Chart: Some Drugs for HFrEF
Med Lett Drugs Ther. 2025 May 26;67(1729):e1-15 doi:10.58347/tml.2025.1729b | Show Introduction Hide Introduction
Drugs for Breast Cancer
Treatment Guidelines from The Medical Letter • Jan 01, 2005 (Issue 29)
tamoxifen.
AROMATASE INHIBITORS — Aromatase
inhibitors block conversion of adrenal androgens ...
In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for metastatic disease. A summary of individual drugs and their adverse effects begins on page 3.
Oral Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2000 (Issue 1078)
to be less androgenic. They have been associated with a small increase in the risk of
venous thromboembolism ...
Two types of oral contraceptives are available in the USA: combination oral contraceptives that contain both an estrogen and a progestin, and progestin-only contraceptives, or "mini-pills."Used as directed, all oral contraceptives marketed in the USA are similarly effective in preventing pregnancy.
Drugs That Cause Sexual Dysfunction: An Update
The Medical Letter on Drugs and Therapeutics • Aug 07, 1992 (Issue 876)
, The effect of long-term administration of digoxin on plasma androgens and sexual dysfunction. J Sex Marital ...
Many commonly used drugs can interfere with sexual function in both men and women, causing loss of libido, interfering with erection or ejaculation in men, and delaying or preventing orgasm in women. Drug-related effects on sexual function may be difficult to distinguish from the effects of depression or disease, but most are reversible when drug use is stopped and sometimes when dosage is decreased. Since many patients are reluctant to talk about sexual difficulties, physicians may wish to ask about the possibility of drug-induced sexual dysfunction, particularly when they have...
Acute Reactions to Drugs of Abuse
The Medical Letter on Drugs and Therapeutics • Mar 04, 2002 (Issue 1125)
or androgenic steroids abused by athletes to enhance
strength can cause aggressiveness, irritability, impaired ...
Acute toxic reactions to drugs of abuse continue to be important problems. Some patients may have mixed intoxications with complex combinations of signs and symptoms.
Addendum: Aducanumab (Aduhelm) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021 (Issue 1629)
reactions, but severe reactions
are uncommon.19 Estrogenic and anti-androgenic
activities ...
In June 2021, the FDA approved the IV amyloid beta-directed
monoclonal antibody aducanumab (Aduhelm) for treatment
of Alzheimer’s disease. The approval did not restrict use of
the drug to patients with mild cognitive impairment or mild
dementia, which was the population enrolled in the clinical
trials. Now, Biogen, with the permission of the FDA, has made
an addition to the labeling of the drug that says: Treatment with
Aduhelm should be initiated in patients with mild cognitive
impairment or mild dementia stage of disease, the population
in which treatment was initiated in clinical...
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
into active
metabolites of estrogens and androgens. Prasterone
can be used as an alternative to a vaginal ...
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection. Vasomotor
symptoms (VMS; hot flashes, night sweats) often
disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 doi:10.58347/tml.2024.1697a | Show Introduction Hide Introduction
Sunscreens
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025 (Issue 1731)
, but severe reactions
are uncommon.24 Estrogenic and anti-androgenic
activity and neurotoxicity ...
Excessive exposure to ultraviolet (UV) radiation can
cause erythema, photoaging, and skin cancer.
Sunscreens are widely used to reduce these risks, but
questions remain about their effectiveness and safety.
In 2021, the FDA proposed a rule that would require
additional safety studies for some sunscreen active
ingredients and mandate better UVA protection in
sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102 doi:10.58347/tml.2025.1731a | Show Introduction Hide Introduction
Comparison Table: Some Oral Antiseizure Medications (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
, and
with increased androgen
concentrations in men
Rare: fatal hepatic failure,
life-threatening pancreatitis ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40 doi:10.58347/tml.2024.1708b | Show Introduction Hide Introduction
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • May 26, 2025 (Issue 1729)
treatment.
Spironolactone has anti-androgenic activity; it can
cause erectile dysfunction and painful ...
Pharmacologic management of chronic heart failure
(HF) is primarily determined by the patient's left
ventricular ejection fraction (LVEF) and severity of
symptoms. Patients with chronic HF who have an
LVEF ≤40% are considered to have heart failure with
reduced ejection fraction (HFrEF) and those with an
LVEF ≥50% are considered to have heart failure with
preserved ejection fraction (HFpEF). Patients with an
LVEF of 41-49% have heart failure with mildly reduced
or mid-range ejection fraction.
Med Lett Drugs Ther. 2025 May 26;67(1729):81-8 doi:10.58347/tml.2025.1729a | Show Introduction Hide Introduction